← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dignify Therapeutics, Llc
Research Triangle Park, NC
$21,157,667
Total funding
20
Grants
Funding over time
peak $3.5M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,276,598 · 19
DOD$1,881,069 · 1
By mechanism
R44$6,995,559 · 4
U44$6,905,476 · 2
R43$2,420,871 · 8
—$1,881,069 · 1
R42$1,364,621 · 1
R41$889,071 · 3
Investigators at Dignify Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
INTRARECTAL MECHANORECEPTOR SENSITIZATION TO INDUCE DEFECATION AFTER SPINAL INJURY$1,881,069
· FY2025 · Defense Health Agency
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding$1,823,630
U44 · FY2020 · NS
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding$1,473,895
U44 · FY2024 · NS
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding$1,187,722
U44 · FY2021 · NS
An optimized NK2R agonist for 'on-demand' voiding$1,158,181
R44 · FY2017 · AG
Development of a first-in-class therapeutic for producing 'on-demand' voiding$1,001,467
R44 · FY2018 · DK
Development of a first-in-class therapeutic for producing 'on-demand' voiding$998,525
R44 · FY2019 · DK
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding$976,908
U44 · FY2025 · NS
Delivery of peptides for inducing voiding associated with neurological retention$953,265
R42 · FY2016 · NS
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$941,206
R44 · FY2020 · NS
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding$901,425
U44 · FY2019 · NS
Development of a treatment for voiding dysfunction in spinal cord injured patients$818,347
R44 · FY2016 · HD
Development of a treatment for voiding dysfunction in spinal cord injured patients$681,653
R44 · FY2017 · HD
An optimized NK2R agonist for 'on-demand' voiding$614,817
R44 · FY2018 · AG
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding$499,393
U44 · FY2023 · NS
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$431,363
R44 · FY2021 · NS
Delivery of peptides for inducing voiding associated with neurological retention$411,356
R42 · FY2017 · NS
Examination of a novel potential therapy for autonomic dysreflexia$394,754
R41 · FY2020 · NS
Therapy for Fecal Incontinence and FecalUrgency$391,458
R43 · FY2024 · DK
Novel treatment for urinary incontinence and overactive bladder symptoms in the elderly$389,852
R43 · FY2024 · AG